Prospective phase IIb study of AADC gene therapy in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Trial Profile

Prospective phase IIb study of AADC gene therapy in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs AAV-hAADC (Primary)
  • Indications Inborn error amino acid metabolic disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 According to an Agilis Biotherapeutics media release, The Company may extend the Phase IIb study to permit the treatment of additional patients in need of therapeutic intervention while it undertakes activities in support of the approval of AGIL-AADC in multiple countries around the world.
    • 03 Oct 2017 According to an Agilis Biotherapeutics media release, dosing of the last of six planned patients has been completed.
    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to an Agilis Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top